Hikari Power Ltd bought a new position in shares of Ocular Therapeutix Inc (NASDAQ:OCUL) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 80,011 shares of the biopharmaceutical company’s stock, valued at approximately $356,000. Hikari Power Ltd owned 0.27% of Ocular Therapeutix at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of OCUL. TIAA CREF Investment Management LLC lifted its holdings in Ocular Therapeutix by 0.7% in the second quarter. TIAA CREF Investment Management LLC now owns 111,019 shares of the biopharmaceutical company’s stock worth $1,029,000 after buying an additional 785 shares during the period. Nationwide Fund Advisors lifted its holdings in Ocular Therapeutix by 10.8% in the second quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,204 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Ocular Therapeutix by 4.4% in the second quarter. Goldman Sachs Group Inc. now owns 33,417 shares of the biopharmaceutical company’s stock worth $310,000 after buying an additional 1,422 shares during the period. Teachers Advisors LLC lifted its holdings in Ocular Therapeutix by 6.2% in the second quarter. Teachers Advisors LLC now owns 42,679 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 2,500 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Ocular Therapeutix by 0.4% in the second quarter. Vanguard Group Inc. now owns 905,456 shares of the biopharmaceutical company’s stock worth $8,394,000 after buying an additional 3,194 shares during the period. Institutional investors own 53.11% of the company’s stock.
Shares of Ocular Therapeutix Inc (OCUL) traded down $0.30 on Friday, hitting $5.18. 675,531 shares of the company traded hands, compared to its average volume of 551,488. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39. Ocular Therapeutix Inc has a 12 month low of $3.30 and a 12 month high of $11.79. The company has a market capitalization of $142.28, a P/E ratio of -2.28 and a beta of 1.53.
Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The business had revenue of $523.00 million during the quarter, compared to the consensus estimate of $0.52 million. During the same quarter in the previous year, the firm posted ($0.39) EPS. The firm’s revenue was up 9.6% on a year-over-year basis. equities analysts predict that Ocular Therapeutix Inc will post -2.31 earnings per share for the current fiscal year.
In other Ocular Therapeutix news, insider Antony C. Mattessich purchased 21,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were acquired at an average price of $4.29 per share, for a total transaction of $90,090.00. Following the purchase, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $90,090. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Amarpreet Sawhney purchased 19,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were acquired at an average price of $5.18 per share, for a total transaction of $98,420.00. Following the purchase, the chairman now directly owns 696,390 shares in the company, valued at $3,607,300.20. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 69,500 shares of company stock valued at $304,781. 26.10% of the stock is currently owned by insiders.
A number of equities analysts have weighed in on the stock. ValuEngine downgraded shares of Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research note on Friday. BTIG Research raised shares of Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research note on Friday, January 19th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, November 8th. Zacks Investment Research downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Finally, Guggenheim assumed coverage on shares of Ocular Therapeutix in a research note on Monday, October 23rd. They set a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.67.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/03/hikari-power-ltd-takes-356000-position-in-ocular-therapeutix-inc-ocul.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.